



S. JORDAN ASSOCIATES

LIFE SCIENCES CONSULTANT & REGISTERED REPRESENTATIVE

CAPABILITIES

For Institutional Investors Use Only

Securities are offered through Finalis Securities LLC Member FINRA/SIPC.
S. Jordan Associates and Finalis Securities LLC are separate, unaffiliated entities.



DISCLOSURE STATEMENT

This presentation, including without limitation any information, estimates or projections contained herein or made in connection with this presentation, either in writing or orally or other format, (this "Presentation") is being furnished by or on behalf of The Translational Genomics Research Institute ("Company"). Any information contained in this Presentation is for informational purposes only and has not been independently verified. The Presentation may contain confidential and/or proprietary information and is provided for the exclusive use of the recipient and may not be reproduced, provided or disclosed to others, or used for any other purpose, without written authorization by S. Jordan Associates and the Company, and upon request must be returned to the Company or S. Jordan Associates.

S. Jordan Associates is not a Registered Investment Advisor, Broker/Dealer, Financial Analyst, Financial Bank, Securities Broker or Financial Planner, and any recipient of this Presentation acknowledges and agrees that S. Jordan Associates is not acting, nor is required to act, in any such capacity in connection with any transaction involving the Company pertaining to the matters contained herein. This Presentation is not intended to be and does not constitute financial advice or any other advice, is general in nature and not specific to any recipient. Recipients are responsible for their own investment research and investment decisions. Recipients should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained on this Presentation constitutes a solicitation, recommendation, endorsement, or offer by the Company or S. Jordan Associates or any of their affiliates or any third party service provider to buy or sell any securities or other financial instruments in this or in any other jurisdiction in which such solicitation or offer would be unlawful under the securities laws of such jurisdiction. This Presentation does not address the circumstances of any particular individual or entity. S. Jordan Associates is not a fiduciary by virtue of any person's use of or access to this Presentation or the information contained herein. Recipients alone assume the sole responsibility of evaluating the merits and risks associated with the use of any information or other content in this Presentation before making any decisions based on such information or other content.

The Company, S. Jordan and Associates and their respective affiliates make no representation or warranty (express or implied) as to the accuracy or completeness of this Presentation and none of them will have any liability for any recipient's use of this Presentation or any other oral, written, or other communications transmitted to the recipient in the course of its evaluation of the Company, including without limitation, any improper use or defamatory, offensive, or illegal conduct of recipient or any other users. This Presentation is provided on an "as is" basis without warranties of any kind, either express or implied, including but not limited to warranties of title or implied warranties of merchantability or fitness for a particular purpose. The disclaimers of liability contained herein apply to any damages or injury caused by any failure of performance, error, omission, interruption, deletion, defect, delay in operation or transmission, computer virus, communication line failure, theft or destruction or unauthorized access to, alteration of, or use of record, whether for breach of contract, tortious behavior, negligence, or under any other cause of action. In exchange for accessing this Presentation, recipients agree not to hold Company or S. Jordan Associates or any of their affiliates or any third-party service provider liable for any possible claim for damages arising from any use by or decision made by recipients based on information or other content made available to recipients in or through this Presentation.

Any recipient of this Presentation acknowledges and agrees that the Company, S. Jordan Associates and their affiliates are not liable for any use of this Presentation or reliance on any information from this Presentation. In no event will the Company, S. Jordan Associates or any of their affiliates be liable for any direct, indirect, incidental, special, or consequential damages (including but not limited to lost profits or trading losses) arising out of the use of or inability to use this Presentation. S. Jordan Associates and their affiliates do not endorse and are not responsible for the accuracy or reliability of any opinion, advice, information or statement on this Presentation.

This Presentation includes certain forward-looking statements, estimates and projections provided by, and with respect to the anticipated future performance of, the Company. In some cases, recipients can identify forward-looking statements by terminology such as "may", "estimates", "anticipates", "intends", "will", "should", "could", "expects", "believes", or "predicts". Such statements, estimates, and projections reflect various assumptions and elements of subjective judgment made by management concerning anticipated results, which are subject to business, economic, and competitive uncertainties and contingencies, many of which are beyond the control of the Company and which may or may not prove to be correct. This Presentation contains certain projected financial information that reflects management's projections as to anticipated future results based upon assumptions that are inherently uncertain, including assumptions as to the size of the market in which it competes, general industry conditions, and other factors. The assumptions are based upon management's judgment. As a result, no representation or warranty is made as to the feasibility of the projected financial information included in this Presentation.

This Presentation is not, and under no circumstances should be construed as, a solicitation to act as a securities broker or dealer in any jurisdiction. Recipients should not regard this Presentation as a substitute for the exercise of their own judgment. The Company reserves the right to negotiate with one or more prospective third parties at any time and to enter into a definitive agreement relating to a transaction with the Company without prior notice to the recipient or other prospective third parties. Also, the Company reserves the right, at any time, to terminate the further participation in the investigation and process by any party and to modify any procedures without giving advance notice or providing any reason thereof. The Company also reserves the right during the evaluation period to take any action, whether within or outside the ordinary course of business. Neither this Presentation nor its delivery to recipients shall constitute or be construed to be an offer to sell any securities of the Company. Neither the Company nor S. Jordan Associates expects to update or otherwise revise this Presentation or other materials supplied herewith.



OPERATIONAL, BUSINESS DEVELOPMENT, AND BANKING EXPERIENCE



SCOTT JORDAN

FOUNDER / CEO

<https://www.linkedin.com/in/sjordan1/>

- C-Level Operations Experience – Chief Financial Officer (CFO) / Chief Business Officer (CBO) for private and public (NASDAQ) biotechnology companies leveraging non-dilutive funding, strategic partnerships, and the capital markets to advance development programs through proof-of-concept clinical studies
- Business Development / Investment Banking Expertise – Over 30 years of structuring licensing agreements, closing Seed / Series rounds, cross-over financings, equity lines, and S1 / S3 shelf offerings
- Facilitated "Exits" via Mergers and Acquisition (M&A), Initial Public Offerings (IPOs), and Alternative Public Offerings (APOs - Special Purpose Acquisition Companies - SPAC / reverse mergers)



COREY MENDOZA

CHIEF MARKETING OFFICER

<https://www.linkedin.com/in/coreymendoza/>

- A multiple award-winning Executive Producer, Writer, Director, Editor, Designer, Musician, and Marketing Strategist with over 25 years of professional experience. His expertise is in brand development, marketing & advertising, video and television production, and creative design.
- AWARDS:
 - (5) Emmy Awards for "Minds of Medicine & "Vital Signs" (NATAS/Mid-Atlantic)
 - (3) Telly Awards for "Best Production" in Television - "Gold Coast Reality"
 - (5) Axiom Awards for "Absolute eXcellence" in Digital Media
 - (3) Silver Mic Awards for Advertising Commercials
 - (2) MarCom Creative for regional Advertising Campaign



LINDA SU

VP, BUSINESS DEVELOPMENT

<https://www.linkedin.com/in/linda-su-60491861/>

- Works across various business development and operational areas including investor relations, intellectual property, finance, and capital raising
- Manages SJA Customer Relations Management (CRM) Cloud-Based Platform, Hubspot, targeting and engaging with potential strategic partners / investors on behalf of life science, medical device, and diagnostic clients





S. JORDAN ASSOCIATES (SJA) SERVICE OFFERINGS

NON-DILUTIVE FUNDING

S. Jordan Associates (SJA) is proficient identifying non-dilutive capital sources from Local, State (Cancer Prevention Research Institute of Texas - CPRIT) and Federally sponsored institutions (NIH / SBIR)

Guide clients through the application process and work collaboratively to implement best practices leading to successful awards



STRATEGIC ADVISORY/ BUSINESS DEVELOPMENT

SJA engages with strategic partners seeking to outsource R&D via traditional and novel partnerships (option-to-buy / licensing, co-development). Services provided to emerging growth companies include:

- Assessing the competitive landscape and benchmarking against industry deal averages (upfront payments, royalties, milestones)
- Targeted outreach to large biopharmaceutical, diagnostic, and medical device companies managed within SJA's proprietary Customer Relationship Management (CRM) system
- Negotiating term sheets with prospective partners optimizing client deal metrics and shareholder return on investment (ROI)

PRIVATE COMPANY FINANCINGS

SJA exceeds client financing objectives by accessing the company's extensive network of institutional, angel groups, and alternative investors (accredited, family offices, hedge funds) to finance early to mid-stage biotech companies through major value inflection points / milestones

Effective at negotiating and closing Seed / Series rounds with institutional capital sources (venture capital, cross-over) and identifying / securing commitments from "Lead" sponsors pivotal to securing investor syndicates



"EXITS" / PUBLIC COMPANY FINANCINGS

SJA works diligently evaluating viable exit / public company financing vehicles including mergers and acquisitions, initial public offerings (IPOs), and alternative public offerings (reverse merger, SPAC) aligned with capital market conditions and company-specific attributes

Alternative Public Offerings (APOs):

Leverage strong relationships with sell-side banks and reverse merger / SPAC sponsors identifying public shells, submitting proposals to win auctions, and negotiating / closing term sheets on behalf of private companies seeking to list on public market exchanges (e.g. NASDAQ)





ACHIEVEMENTS 2021-2022: GENE THERAPY & IMMUNE-ONCOLOGY

NON-DILUTIVE FINANCING – INOMAGEN THERAPEUTICS

- S. Jordan Associates (SJA) acted as financial advisor to Inomagen Therapeutics assisting with securing a \$3.67M NIH SBIR Fast Track Phase 1/2 Grant to develop a novel gene therapy for Atrial Fibrillation (AF)
- The award includes \$462,689 from the National Heart, Lung, and Blood Institute (NHLBI) to complete the 'Phase 1' segment of development which includes optimizing gene doses and electroporation parameters required for atrial gene delivery
- Upon successful completion of the Phase 1 segment, RTI eligible to receive an additional \$3,212,600 in NIH funding to carry out the 'Phase 2' segment, which will include determining optimal dose of gene therapy required to attenuate established electrical remodeling in AF

ABOUT INOMAGEN THERAPEUTICS, <https://inomagen.com>

- Inomagen Therapeutics, Inc. is a privately held biotechnology company with technology licensed from Northwestern University (NU) dedicated to delivering the promise of gene therapy for treating serious cardiovascular diseases such as atrial fibrillation



**\$3.67M NIH SBIR
Fast Track Grant**



**Non-Dilutive
Funding**



PRIVATE COMPANY FINANCING – IMMUNOGENESIS

- S. Jordan Associates (SJA) acted as financial advisor to ImmunoGenesis assisting with raising a \$14.5M convertible note
- Lead investors include the founders of Chicago-based hedge funds (Magnetar Capital and Peak6), early-stage venture capitalists (BioAdvance, Texas Halo Fund) and secondary markets trading firm / cross-over investor (Adit Ventures)

ABOUT IMMUNOGENESIS, <https://www.immunogenesis.com/>

- ImmunoGenesis formed to develop products from the lab of Dr. Michael A. Curran, Associate Professor, Department of Immunology at MD Anderson Cancer Center who worked closely with Nobel Laureate, Dr. James Allison, and is on the patent for CTLA-4 (cytotoxic T-lymphocyte-associated protein 4 – Ipilimumab / Yervoy) inhibition
- Development programs to overcome immune resistance in "cold" tumors unresponsive to current checkpoint inhibition therapies which comprise the majority of all cancers



**\$14.5M
Convertible Note**



**Private
Placement**



ACHIEVEMENTS: 2016 - 2020

NON-DILUTIVE FUNDING

- Secured awards from the Cancer Prevention Research Institute of Texas (CPRIT) resulting in ~\$35M of non-dilutive capital advancing three drug programs through Investigational New Drug (IND) enabling studies
- Leveraged non-dilutive capital during early stages of development to reach critical milestones resulted in subsequent financing rounds priced at higher valuations




STRATEGIC ADVISORY/ BUSINESS DEVELOPMENT

- Out-licensed South Korean rights to Salius Pharmaceuticals / Iterion Therapeutics' lead compounds (Secclidemstat, Tegavivint) to HLB Lifesciences Co.
- Negotiated licensing terms including upfront payment, milestones, and royalties
- Established joint research committees monitoring progress and report findings to respective board members




PRIVATE COMPANY FINANCINGS

- Raised development funding from academic Institutions, angel groups, and accredited / institutional investors (venture capital)



"EXITS" / PUBLIC COMPANY FINANCINGS

- Identified, awarded, negotiated, and closed a term sheet / public shell with Flex Pharma (FLRX) resulting in Salius Pharmaceuticals listing on NASDAQ via a reverse merger in 2019
- Facilitated a \$10.9M equity line with Aspire Capital, a private, long-only investment fund focused on making investments in publicly traded companies
- Closed a \$11M S1 offering with Ladenburg Thalmann funding Salius through Phase 1 / 2 clinical milestones





TOMBSTONES: 2016 - 2020

SERIES 1



\$1.6M Convertible Note

SERIES A



\$6.4M Convertible Preferred

REVERSE MERGER



FLEXPharma

\$46.3M Deal Value

EQUITY LINE



AspireCapital

\$10.9M in Common Stock

S1 OFFERING



\$11.0M in Common Stock

SERIES A1 / A2



\$10.0M Convertible Preferred

SERIES SEED



\$2M in Proceeds

S. KOREAN RIGHTS



\$1M Upfront Payment

Capital raises and licensing agreements facilitated as an executive (CFO / CBO) of Salaris Pharmaceuticals and Iterion Therapeutics



TRANSACTION HISTORY: 2005 - 2016



CLOSED \$583M IN LICENSING AGREEMENTS / PARTNERSHIPS



LICENSOR	TOTAL DEAL VALUE \$M	LICENSEE
	\$125	
	\$200	
	\$50	
	\$150	



RAISED \$152M – PRIVATE PLACEMENTS



DEAL VALUE \$M

\$15	\$60	\$6
		

RAISED \$194 M – IPO / SECONDARY OFFERINGS / M&A



DEAL VALUE \$M

\$52 - IPO	\$74 - SECONDARY	\$6 - M&A
		
		

Capital raises, licensing agreements, and M&A / public offerings facilitated as a placement agent of S. Jordan Associates and Healthios Capital Markets.



AI/ Machine Learning – IQ500

Securities are offered through Finalis Securities LLC Member FINRA/SIPC.
S. Jordan Associates and Finalis Securities LLC are separate, unaffiliated entities.



SJA Partnered with IQ500 – Leader in AI / Machine Learning

IQ.500 connects Issuers, Investors and Strategic acquirors directly via an intelligent infrastructure that modernizes the entire private investment continuum from investment research and market analysis, to relationship mapping, networking, opportunity screening, communication, transaction management, due diligence, FAQ's, valuation, syndication, deal execution, benchmarking, performance measurement and exit planning.

Powered by machine learning which accurately predicts investments with 93% statistical precision, I.Q.500 seeks to transform the efficiency of the \$480 billion Venture Capital market by streamlining investment selection, risk management and outcome realization

- Machine Learning Algorithm: Trained on 2 million VC transactions using 160 million analytical arrays across 800 dimensional vectors





IQ500 – Right Person, Right Deal, Right Time

WHICH INVESTORS ARE BEST FOR THE COMPANY?

Financial and strategic targets which are 93% likely to lead the Company's next transaction.



WHO DO WE CONTACT? WHY? HOW?

Individual target contact affiliations.
Direct, encrypted, "1:1"
communication through MS Teams



WILL THERE BE INTEREST IN OUR DEAL?



Real-time, "in aggregate" data of activity by financial and strategic targets on Company listing

WHEN WILL THE DEAL CLOSE?



KPI's, including strength of relationships; deal quality; likelihood of success; timing of close.





IQ500 – Benefits for Issuers

Each Company listing on IQ500 features a range of deal experiences – solving the most important problems – and intended to support financial and strategic success throughout the business horizon.

HOW DO WE COMPARE ?


Peer Groups which place each Company among its closest “competitors”, as established by investors and strategic participants on Company’s target lists.



Company	Revenue	Profit	EBITDA	Operating Profit	Net Income	EPS	Dividend	Payout Ratio	Market Cap	Enterprise Value	EV/EBITDA	EV/Operating Profit	EV/Net Income	EV/Dividend
Alpha Industries Inc.	1,200	250	300	280	260	1.50	0.50	33%	1,200	1,200	4.0x	4.7x	5.0x	2.4x
Beta Services Group	1,100	240	290	270	250	1.40	0.45	32%	1,100	1,100	3.9x	4.6x	4.9x	2.3x
Gamma Tech Inc.	1,300	260	310	290	270	1.60	0.55	34%	1,300	1,300	4.1x	4.8x	5.1x	2.5x
Delta Corp.	1,400	270	320	300	280	1.70	0.60	35%	1,400	1,400	4.2x	4.9x	5.2x	2.6x
Epsilon Energy Ltd.	1,500	280	330	310	290	1.80	0.65	36%	1,500	1,500	4.3x	5.0x	5.3x	2.7x
Zeta Financial Inc.	1,600	290	340	320	300	1.90	0.70	37%	1,600	1,600	4.4x	5.1x	5.4x	2.8x
Eta Pharmaceuticals	1,700	300	350	330	310	2.00	0.75	38%	1,700	1,700	4.5x	5.2x	5.5x	2.9x
Theta Biotech Inc.	1,800	310	360	340	320	2.10	0.80	39%	1,800	1,800	4.6x	5.3x	5.6x	3.0x
Iota Chemicals Ltd.	1,900	320	370	350	330	2.20	0.85	40%	1,900	1,900	4.7x	5.4x	5.7x	3.1x
Kappa Metals Inc.	2,000	330	380	360	340	2.30	0.90	41%	2,000	2,000	4.8x	5.5x	5.8x	3.2x
Lambda Energy Corp.	2,100	340	390	370	350	2.40	0.95	42%	2,100	2,100	4.9x	5.6x	5.9x	3.3x
Mu Chemicals Ltd.	2,200	350	400	380	360	2.50	1.00	43%	2,200	2,200	5.0x	5.7x	6.0x	3.4x
Nu Pharmaceuticals	2,300	360	410	390	370	2.60	1.05	44%	2,300	2,300	5.1x	5.8x	6.1x	3.5x
Xi Biotech Inc.	2,400	370	420	400	380	2.70	1.10	45%	2,400	2,400	5.2x	5.9x	6.2x	3.6x
Omicron Chemicals Ltd.	2,500	380	430	410	390	2.80	1.15	46%	2,500	2,500	5.3x	6.0x	6.3x	3.7x
Pi Energy Corp.	2,600	390	440	420	400	2.90	1.20	47%	2,600	2,600	5.4x	6.1x	6.4x	3.8x
Rho Chemicals Ltd.	2,700	400	450	430	410	3.00	1.25	48%	2,700	2,700	5.5x	6.2x	6.5x	3.9x
Sigma Pharmaceuticals	2,800	410	460	440	420	3.10	1.30	49%	2,800	2,800	5.6x	6.3x	6.6x	4.0x
Tau Biotech Inc.	2,900	420	470	450	430	3.20	1.35	50%	2,900	2,900	5.7x	6.4x	6.7x	4.1x
Upsilon Chemicals Ltd.	3,000	430	480	460	440	3.30	1.40	51%	3,000	3,000	5.8x	6.5x	6.8x	4.2x
Phi Energy Corp.	3,100	440	490	470	450	3.40	1.45	52%	3,100	3,100	5.9x	6.6x	6.9x	4.3x
Chi Chemicals Ltd.	3,200	450	500	480	460	3.50	1.50	53%	3,200	3,200	6.0x	6.7x	7.0x	4.4x
Psi Pharmaceuticals	3,300	460	510	490	470	3.60	1.55	54%	3,300	3,300	6.1x	6.8x	7.1x	4.5x
Omega Biotech Inc.	3,400	470	520	500	480	3.70	1.60	55%	3,400	3,400	6.2x	6.9x	7.2x	4.6x
Kappa Chemicals Ltd.	3,500	480	530	510	490	3.80	1.65	56%	3,500	3,500	6.3x	7.0x	7.3x	4.7x
Lambda Energy Corp.	3,600	490	540	520	500	3.90	1.70	57%	3,600	3,600	6.4x	7.1x	7.4x	4.8x
Mu Chemicals Ltd.	3,700	500	550	530	510	4.00	1.75	58%	3,700	3,700	6.5x	7.2x	7.5x	4.9x
Nu Pharmaceuticals	3,800	510	560	540	520	4.10	1.80	59%	3,800	3,800	6.6x	7.3x	7.6x	5.0x
Xi Biotech Inc.	3,900	520	570	550	530	4.20	1.85	60%	3,900	3,900	6.7x	7.4x	7.7x	5.1x
Omicron Chemicals Ltd.	4,000	530	580	560	540	4.30	1.90	61%	4,000	4,000	6.8x	7.5x	7.8x	5.2x
Pi Energy Corp.	4,100	540	590	570	550	4.40	1.95	62%	4,100	4,100	6.9x	7.6x	7.9x	5.3x
Rho Chemicals Ltd.	4,200	550	600	580	560	4.50	2.00	63%	4,200	4,200	7.0x	7.7x	8.0x	5.4x
Sigma Pharmaceuticals	4,300	560	610	590	570	4.60	2.05	64%	4,300	4,300	7.1x	7.8x	8.1x	5.5x
Tau Biotech Inc.	4,400	570	620	600	580	4.70	2.10	65%	4,400	4,400	7.2x	7.9x	8.2x	5.6x
Upsilon Chemicals Ltd.	4,500	580	630	610	590	4.80	2.15	66%	4,500	4,500	7.3x	8.0x	8.3x	5.7x
Phi Energy Corp.	4,600	590	640	620	600	4.90	2.20	67%	4,600	4,600	7.4x	8.1x	8.4x	5.8x
Chi Chemicals Ltd.	4,700	600	650	630	610	5.00	2.25	68%	4,700	4,700	7.5x	8.2x	8.5x	5.9x
Psi Pharmaceuticals	4,800	610	660	640	620	5.10	2.30	69%	4,800	4,800	7.6x	8.3x	8.6x	6.0x
Omega Biotech Inc.	4,900	620	670	650	630	5.20	2.35	70%	4,900	4,900	7.7x	8.4x	8.7x	6.1x
Kappa Chemicals Ltd.	5,000	630	680	660	640	5.30	2.40	71%	5,000	5,000	7.8x	8.5x	8.8x	6.2x
Lambda Energy Corp.	5,100	640	690	670	650	5.40	2.45	72%	5,100	5,100	7.9x	8.6x	8.9x	6.3x
Mu Chemicals Ltd.	5,200	650	700	680	660	5.50	2.50	73%	5,200	5,200	8.0x	8.7x	9.0x	6.4x
Nu Pharmaceuticals	5,300	660	710	690	670	5.60	2.55	74%	5,300	5,300	8.1x	8.8x	9.1x	6.5x
Xi Biotech Inc.	5,400	670	720	700	680	5.70	2.60	75%	5,400	5,400	8.2x	8.9x	9.2x	6.6x
Omicron Chemicals Ltd.	5,500	680	730	710	690	5.80	2.65	76%	5,500	5,500	8.3x	9.0x	9.3x	6.7x
Pi Energy Corp.	5,600	690	740	720	700	5.90	2.70	77%	5,600	5,600	8.4x	9.1x	9.4x	6.8x
Rho Chemicals Ltd.	5,700	700	750	730	710	6.00	2.75	78%	5,700	5,700	8.5x	9.2x	9.5x	6.9x
Sigma Pharmaceuticals	5,800	710	760	740	720	6.10	2.80	79%	5,800	5,800	8.6x	9.3x	9.6x	7.0x
Tau Biotech Inc.	5,900	720	770	750	730	6.20	2.85	80%	5,900	5,900	8.7x	9.4x	9.7x	7.1x
Upsilon Chemicals Ltd.	6,000	730	780	760	740	6.30	2.90	81%	6,000	6,000	8.8x	9.5x	9.8x	7.2x
Phi Energy Corp.	6,100	740	790	770	750	6.40	2.95	82%	6,100	6,100	8.9x	9.6x	9.9x	7.3x
Chi Chemicals Ltd.	6,200	750	800	780	760	6.50	3.00	83%	6,200	6,200	9.0x	9.7x	10.0x	7.4x
Psi Pharmaceuticals	6,300	760	810	790	770	6.60	3.05	84%	6,300	6,300	9.1x	9.8x	10.1x	7.5x
Omega Biotech Inc.	6,400	770	820	800	780	6.70	3.10	85%	6,400	6,400	9.2x	9.9x	10.2x	7.6x
Kappa Chemicals Ltd.	6,500	780	830	810	790	6.80	3.15	86%	6,500	6,500	9.3x	10.0x	10.3x	7.7x
Lambda Energy Corp.	6,600	790	840	820	800	6.90	3.20	87%	6,600	6,600	9.4x	10.1x	10.4x	7.8x
Mu Chemicals Ltd.	6,700	800	850	830	810	7.00	3.25	88%	6,700	6,700	9.5x	10.2x	10.5x	7.9x
Nu Pharmaceuticals	6,800	810	860	840	820	7.10	3.30	89%	6,800	6,800	9.6x	10.3x	10.6x	8.0x
Xi Biotech Inc.	6,900	820	870	850	830	7.20	3.35	90%	6,900	6,900	9.7x	10.4x	10.7x	8.1x
Omicron Chemicals Ltd.	7,000	830	880	860	840	7.30	3.40	91%	7,000	7,000	9.8x	10.5x	10.8x	8.2x
Pi Energy Corp.	7,100	840	890	870	850	7.40	3.45	92%	7,100	7,100	9.9x	10.6x	10.9x	8.3x
Rho Chemicals Ltd.	7,200	850	900	880	860	7.50	3.50	93%	7,200	7,200	10.0x	10.7x	11.0x	8.4x
Sigma Pharmaceuticals	7,300	860	910	890	870	7.60	3.55	94%	7,300	7,300	10.1x	10.8x	11.1x	8.5x
Tau Biotech Inc.	7,400	870	920	900	880	7.70	3.60	95%	7,400	7,400	10.2x	10.9x	11.2x	8.6x
Upsilon Chemicals Ltd.	7,500	880	930	910	890	7.80	3.65	96%	7,500	7,500	10.3x	11.0x	11.3x	8.7x
Phi Energy Corp.	7,600	890	940	920	900	7.90	3.70	97%	7,600	7,600	10.4x	11.1x	11.4x	8.8x
Chi Chemicals Ltd.	7,700	900	950	930	910	8.00	3.75	98%	7,700	7,700	10.5x	11.2x	11.5x	8.9x
Psi Pharmaceuticals	7,800	910	960	940	920	8.10	3.80	99%	7,800	7,800	10.6x	11.3x	11.6x	9.0x
Omega Biotech Inc.	7,900	920	970	950	930	8.20	3.85	100%	7,900	7,900	10.7x	11.4x	11.7x	9.1x
Kappa Chemicals Ltd.	8,000	930	980	960	940	8.30	3.90	100%	8,000	8,000	10.8x	11.5x	11.8x	9.2x
Lambda Energy Corp.	8,100	940	990	970	950	8.40	3.95	100%	8,100	8,100	10.9x	11.6x	11.9x	9.3x
Mu Chemicals Ltd.	8,200	950	1,000	980	960	8.50	4.00	100%	8,200	8,200	11.0x	11.7x	12.0x	9.4x
Nu Pharmaceuticals	8,300	960	1,010	990	970	8.60	4.05	100%	8,300	8,300	11.1x	11.8x	12.1x	9.5x
Xi Biotech Inc.	8,400	970	1,020	1,000	980	8.70	4.10	100%	8,400	8,400	11.2x	11.9x	12.2x	9.6x
Omicron Chemicals Ltd.	8,500	980	1,030	1,010	990	8.80	4.15	100%	8,500	8,500	11.3x	12.0x	12.3x	9.7x
Pi Energy Corp.	8,600	990	1,040	1,020	1,000	8.90	4.20	100%	8,600	8,600	11.4x	12.1x	12.4x	9.8x
Rho Chemicals Ltd.	8,700	1,000	1,050	1,030	1,010	9.00	4.25	100%	8,700	8,700	11.5x	12.2x	12.5x	9.9x
Sigma Pharmaceuticals	8,800	1,010	1,060	1,040	1,020	9.10	4.30	100%	8,800	8,800	11.6x	12.3x	12.6x	10.0x
Tau Biotech Inc.	8,900	1,020	1,070	1,050	1,030	9.20	4.35	100%	8,900	8,900	11.7x	12.4x	12.7x	10.1x
Upsilon Chemicals Ltd.	9,000	1,030	1,080	1,060	1,040	9.30	4.40	100%	9,000	9,000	11.8x	12.5x	12.8x	10.2x
Phi Energy Corp.	9,100	1,040	1,090	1,070	1,050	9.40	4.45	100%	9,100	9,100	11.9x	12.6x	12.9x	10.3x
Chi Chemicals Ltd.	9,200	1,050	1,100	1,080	1,060	9.50	4.50	100%	9,200	9,200	12.0x	12.7x	13.0x	10.4x
Psi Pharmaceuticals	9,300	1,060	1,110	1,090	1,070	9.60	4.55	100%	9,300	9,300	12.1x	12.8x	13.1x	10.5x
Omega Biotech Inc.	9,400	1,070	1,120	1,100	1,080	9.70	4.60	100%	9,400	9,400	12.2x	12.9x	13.2x	10.6x
Kappa Chemicals Ltd.	9,500	1,080	1,130	1,110	1,090	9.80	4.65	100%	9,500	9,500	12.3x	13.0x	13.3x	10.7x
Lambda Energy Corp.	9,600	1,090	1,140	1,120	1,100	9.90	4.70	100%	9,600	9,600	12.4x	13.1x	13.4x	10.8x
Mu Chemicals Ltd.	9,700	1,100	1,150	1,130	1,110	10.00	4.75	100%	9,700	9,700	12.5x	13.2x	13.5x	10.9x
Nu Pharmaceuticals	9,800	1,110	1,160	1,140	1,120	10.10	4.80	100%	9,800	9,800	12.6x	13.3x	13.6x	11.0x
Xi Biotech Inc.	9,900	1,120	1,170	1,1,										



Optimize Investor Target List / Engagement / Transaction Closing






MARKETING / HUBSPOT (CRM)

Securities are offered through Finalis Securities LLC Member FINRA/SIPC.
S. Jordan Associates and Finalis Securities LLC are separate, unaffiliated entities.



EMAIL MARKETING: NUTURING RELATIONSHIPS THROUGH EMAIL CHANNEL





EMAIL MARKETING STRATEGY: OPTIMAL MESSAGE, AUDIENCE, TIME



Messaging content

General outreach /
Brand recognition

News update

Event sign up

Collaboration announcement

Capital raising / Partnering



Targeted audience

Investors

Strategic buyers

Strategic partners

Key opinion leaders

Bankers



Timing

Highest open rate

Highest engagement
rate

Campaign specific time sensitivity



The **Translational Genomics Research Institute** (TGEN) and affiliate of City of Hope, a nonprofit medical research institute dedicated to conducting groundbreaking research, would like to schedule a meeting to discuss their novel pre-clinical CDK7 program.

CDK7 regulates cell cycle and super-enhancer dependent oncogene expression and is correlated with poor prognosis in many cancers (e.g. breast, gastric, hepatocellular, epithelial ovarian, pancreatic cancers).



TGEN's lead molecule, T-1092, is a potent (IC_{50} or EC_{50} <100 nM), selective mTOR inhibitor (T-1092) with good oral bioavailability. The drug candidate suppresses tumor growth as a single agent in multiple xenograft models (e.g., Ovarian, MDA-MB-231, and HCT116). In other agents (combination therapies), T-1092 has shown synergistic effects in pancreatic cancer.

TGN-1062 is a 'non-covalent inhibitor' which binds reversibly to its target. This is a significant competitive advantage to covalent inhibitors currently in clinical trials (e.g. EGFR inhibitors) which bind irreversibly given CDK2 is a protein that has a high turnover rate. The reversible nature of the result of TGN-1062's reversible binding, the novel compound has a superior safety profile mitigating toxicity versus covalent inhibitors in pre / clinical studies.

Below are links to the company's non-confidential deck and Calendly if you would like to schedule a call with TGEN to learn more about this promising small molecule program.

TGEN presentation

Schedule a call

Regards,
Scott Jordan
S. Jordan Associates
www.sjordanassociates.com
scott@sjordanassociates.com



UTILIZING HUBSPOT DATA TOOLS (CRM) TO MEASURE SUCCESS



Metrics

Delivery rate

- Delivered
- Bounced
- Spam

Open rate

- Desktop vs. Mobile
- Email providers

Email view time

- Read
- Skimmed
- Glanced



Clicks

HTML click map

- Location of the clicks on the email
- Optimization(s) for button, links, graphics

Clicked link(s)

- Content clicked

Lead scoring

- Content engagement score for prioritization

Auto-advance life cycle stages

- Leads
- Scheduled a call
- Won / Lost


Dashboard

- Performance review
- Team discussion



DATA IS POWER

Follow up communications



Ensure conversations and activities connected to the contact database for continuous learning and optimization?





ALTERNATIVE PUBLIC OFFERINGS

Securities are offered through Finalis Securities LLC Member FINRA/SIPC.
S. Jordan Associates and Finalis Securities LLC are separate, unaffiliated entities.



ALTERNATIVE PUBLIC OFFERINGS (APO) TEAM

STRONG TRACK RECORD OF FACILITATING APO's IN THE LIFE SCIENCES INDUSTRY

APO Webinar, "Reverse Mergers and SPACS:

Are Alternative Public Offerings the New Normal For Biotech's Going Public?" – March 18th, 2021 <https://hubs.ly/H0JLhtK0>



STEPHEN ALICANTI

Partner
DLA Piper, LLC (US)



SCOTT JANSSEN

Managing Director
LS Associates

Part of the broader LifeSci Partner platform supporting over 200 clients with IR, PR, partnering / BD , and virtual CFO services



MIKE MONTGOMERY

Managing Partner
Effectus Group

Public filings, audit preparation, mergers and acquisitions, business combinations, financial due diligence, and integration



SCOTT JORDAN

Founder / CEO
S Jordan Associates

Raise private placements and concurrent financings, licensing / partnership agreements, M&A, and APOs – Reverse / SPAC



APO SERVICES: INCEPTION TO CLOSING TRANSACTIONS

APO COORDINATION

S. Jordan Associates manages **APO** Process on Behalf of Reverse Merger Sponsors / Private Companies Including the facilitation of Public Company Readiness and Capital Supporting Transactions



Legal / Public Company Readiness

Legal

- Legal advice and document preparation / negotiation including M&A, tax and securities law
- SEC disclosure and periodic reporting guidance

Finance / Interim C-Level

- Evaluation and implementation of financial controls
- Recruiting and leading the internal accounting and finance team members
- Investor and public relations strategies and leadership

Accounting / Controls

- Audit readiness
- S-4 prep (F Pages, MDA, Pro Forma)
- Internal controls
- Accurate, reliable and timely KPI and financial reporting

Project Management / Capital Support

Investment Banking

- Forecasting and financial / cash flow modeling
- Capital raises including venture capital (Series A>), concurrent and cross-over financings (PIPES), and public market offerings
- Introduction to reverse merger sponsors
- Term sheet negotiations

Close

Team

STEPHEN ALICANTI

SCOTT JANSSEN

MIKE MONTGOMERY

SCOTT JORDAN





APO PUBLIC READINESS CHECKLIST

Strategic

Have you built an IPO or Reverse Merger roadmap with specific subject matter experts, work stream, and milestones?
Who is the project owner / manager and do they have experience with this complex process?
Has the board reviewed the plan and key dates?
Have you performed a Board "audit" to make sure you have the people, skills, and governance in place to lead a company into and operate effectively as a public company?
Are the internal shareholders and experts on the Board held accountable for their portion of the project?
Have you engaged a team of expert consultants to support the project (e.g. attorney's, financial and technical accounting, consultants, auditors, D&O insurance providers)?
Have you prepared accurate, reliable, and timely financial and scientific reports that will be required as a public company?
Do you have reliable forecasting and subsequent actual to forecast reporting?

Finance / Accounting

Reviewed monthly closing book process / gap analysis necessary?
Team in place to implement financial planning and analysis including the review of budget vs. actual processes?
Audited financials? If not, has the company received quotations from potential auditing firms?
Company discussed with management / Board final selection of auditors?
Company worked with auditors / director of finance from an accounting firm to complete the audit?
Completed a 409A valuation that can be substantiated under PCAOB standards?
Reviewed the cap table ensuring all supporting documentation in place including all financial transactions?
Set up data base to collect company information such as contracts, stock option grants, financial statements for efficient audit process?

Capital Raise

Developed a plan and timeline for next financing?
Completed an investor deck review by Investor Relations and financial experts ensuring synergistic with financial forecasts and budget?
Reviewed 5 / 10-year financial plan and balance sheet?
Reviewed a list of possible Series / Cross-over investors and selected a banker to assist with the process?
Initiated the IPO / Reverse Merger roadmap with estimated timelines, assigned workstreams to stakeholders and consultants?



APPENDIX #1 – SJA PRIVATE PLACEMENT SERVICES AND TIMELINES

Securities are offered through Finalis Securities LLC Member FINRA/SIPC.
S. Jordan Associates and Finalis Securities LLC are separate, unaffiliated entities.



PRIVATE PLACEMENT SERVICE OFFERINGS

	¹ S. Jordan Associates (SJA)	Services	² Finalis / Marketplace	Services	³ IQ500	Services
	<p>SJA is a Chicago / Miami-based investment bank specializing in providing the following services for emerging growth biotechnology, medical device, and diagnostic companies including:</p> <ul style="list-style-type: none"> • Non-Dilutive Capital • Private Placements • M&A • Alternative Public Offerings • Strategic Advisory 		World's fastest growing deal making and management platform powered by the Company's "Marketplace" enabling issuers to raise capital through Finalis' broker dealer syndicate network which comprises over 200 registered representatives.		Connects Issuers, Investors and Strategic acquirors directly via an intelligent infrastructure that modernizes the entire private investment continuum: from investment research and market analysis, to relationship mapping, networking, opportunity screening, communication, transaction management, due diligence, FAQ's, valuation, syndication, deal execution, benchmarking, performance measurement and exit planning.	
Economics Terms						
Engagement Fee / Month						
>\$10,000	*	SJA Banking Engagement				
\$8,000 - \$10,000	*	SJA (+ Equity) - ⁴ Finalis Syndicate Manager (Optional)	*	⁵ Finalis Syndicate - Placement (Optional)	*	Optional
< \$8,000	*	Finalis Syndicate Manager	*	Finalis Syndicate - Placement	*	Optional
None					*	
Success Fee (%)	*	To be Negotiated	*	To be Negotiated	*	To be Negotiated
Term (Months)	*	4-6	*	4-6		Cancellable Monthly
Subscription Fees (\$)					*	\$1,000 / Month

FOOTNOTES

¹ SJA Engagements - Terms and Conditions Contingent Upon Approved Engagement Following SJA Diligence Review

² Finalis Engagement - Terms and Conditions Contingent Upon Approved Engagement Following Finalis Diligence Review


³ AI Platform

⁴ SJA as Syndicate Manager - Oversee Finalis Investor Syndicate Activities

⁵ Finalis Syndicate - Consortium of Registered Representatives Under Agreement to Raise Capital on Behalf of Issuer



PRIVATE PLACEMENTS - TIMELINE





APPENDIX #2 – IPO VS. SPAC

Securities are offered through Finalis Securities LLC Member FINRA/SIPC.
S. Jordan Associates and Finalis Securities LLC are separate, unaffiliated entities.

27 | www.sjordanassociates.com



INITIAL PUBLIC OFFERING (IPO) vs SPAC

	IPO	SPAC
Valuation	Pro: Priced via a Multi-Day Book-Building Process with Multiple Investors Putting in their Orders Con's: IPO Pricing Largely Driven by the Pricing Appetite of a Few Large Accounts; Risk of Underpriced Public Offerings Resulting in Stock Price Increasing Post-Close Representing significant "Value Left on the Table"	Pro's: Higher Valuation - SPAC Price Discovery is Largely a Direct Negotiation Between the SPAC Sponsor and the Target; Concurrent PIPE acts as an Important Source of Price Validation Supporting the Valuation Negotiated by the Sponsor Con's: Higher Valuations Negotiated to Offset Increased Dilution Associated with Sponsor Shares / Warrants; Limiting Number of Companies Eligible to Participate - Higher Enterprise Value Required to Transact
Dilution	Pro: No Dilution From Sponsor Shares / Warrants Con: Sell 25-35% in the Crossover Round + Sell Another 20-30% in the IPO + 'Greenshoe' Dilution	Pro: Because SPACs Replace the Two-Step of Crossover and IPO, Valuations can Approach that of the IPO Itself Resulting in Less Total Dilution (10-15%) Adding Value to Existing Shareholders Con: Additional Dilution Associated with Sponsor Shares, Private Warrants and Public Warrants
Transaction Structure	Rigid Equity Financing Structure with Investors Receiving Preferred Stock, Liquidation Preferences, and Other Protections at Founder's Expense	Flexible Deal Structure With Earnouts Allows Management to Receive Additional Compensation Upon Company Performance
Crossover / Buy Side Allocations	Lower: Especially in IPOs that are Oversubscribed, Crossover / Buy Side Investors Oftentimes Receive Smaller Allocations	Higher: Significant Allocation of Capital to Invest Over Time Especially Meaningful to Large Investment Funds Seeing to Deploy Capital
Optimal Profile: Private Company		(1) Pipeline / Clinical News Flow over Next 1-3 Years (2) Previously Raised \$25 - \$100M in Preferred Stock Financings (3) Access to Crossover Investors



INITIAL PUBLIC OFFERING (IPO) vs SPAC

	IPO	SPAC
Financial Disclosures – SPAC Allowable Disclosures Under PSLRA Review and Subject to Change	Historical Financial Statements Required Stemming From The Private Securities Litigation Reform Act (PSLRA); No Safe Harbor for Forward-Looking Statements	Pro: Safe Harbor for Forward-Looking Statements Applies Providing Companies with More Flexibility to Share Future Earnings Projections Making a Deal More Attractive Especially with Pre-Revenue Companies Con: There's an Emerging Class of Plaintiff Attorney's Looking at the space as a Result
Reduced Investor Risk	N/A	Reduced Investor Risk Given Shares are Redeemable and Oftentimes Receive a Free Warrant Which They Can Keep Even if Not Participating in the De-SPAC
Merger Target	N/A	With a Specific Valuation Mutually Agreed for the Merger, There's a Clear Timetable for Closing the Deal and Trading as a Public Company (the "de-SPAC" process); For a Merger Target, Both the Timeline to Being Public, as well as the Pre-Specified Scale of the Valuation and Capital Raise are Better "Controlled" in a SPAC Process
Post-Finance Outlook	Oftentimes Need to Conduct Several Financing Processes Within 8-12 Months Distracting Management from Company Operations	Public Company with Strong Institutional Investor Base and Access to Public Capital Markets Facilitating Management Focus on Operations
Liquidity	Existing Shareholders Generally Required to Wait Six Months From Closing of the IPO Prior to Selling Shares	Existing Shareholders (Sponsor) Generally Required to Wait One Year From Closing of the Business Combination (De-SPAC) Prior to Selling Shares



APPENDIX #3 – ALTERNATIVE PUBLIC OFFERING (APO) CASE STUDY

Securities are offered through Finalis Securities LLC Member FINRA/SIPC.
S. Jordan Associates and Finalis Securities LLC are separate, unaffiliated entities.



SALARIUS PHARMACEUTICALS REVERSE MERGES INTO FLEX PHARMA

- Salarium Pharmaceutical (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, announced closing a merger with Flex Pharma, Inc.'s wholly owned subsidiary on July 19, 2019
- The newly combined company focused on the continued development of Salarium's clinical pipeline, which targets rare, orphan cancers with lead compound, Seclidemstast, a LSD1 inhibitor (epigenetics validated target)
- Healthios Capital Markets (now Third500 <https://www.third500.com/>) served as financial advisor in the transaction to Salarium Pharmaceuticals and Wedbush PacGrow advised Flex Pharma

Allocation Percentage - from Summary of Proposed Terms	\$M	%
Flex Enterprise Value - "Shell"	\$7.2	
Flex Cash at Close	\$3.1	
Flex Total Fair Value	\$10.3	
Salarium Total Fair Value	\$36.0	
Total Fair Value of Newco	\$46.3	

FLEXPharma



\$46.3M Deal Value

Allocation Percentage


Flex	22.3%
Salarium	77.7%



TIMELINE / MILESTONES FROM INCEPTION TO REVERSE MERGER CLOSING

FLEXPharma

Salarium
PHARMACEUTICALS



Similar results are not guaranteed; based on investor demand and general market factors.



S. JORDAN ASSOCIATES

Life Sciences Consultant & Registered Representative

SCOTT JORDAN
Founder / CEO

512 N. McClurg #4604
Chicago, IL 60611

312-451-6210
scott@sjordanassociates.com
www.sjordanassociates.com



@sjordan1



@sjordanassociat